Format

Send to

Choose Destination
Trends Pharmacol Sci. 2015 Oct;36(10):645-660. doi: 10.1016/j.tips.2015.06.008.

Therapeutic Targeting of Siglecs using Antibody- and Glycan-Based Approaches.

Author information

1
Institute of Biological Chemistry, Academia Sinica, Taipei, Taiwan.
2
Department of Cell and Molecular Biology, The Scripps Research Institute, La Jolla, CA, USA.
3
Department of Chemical Physiology, The Scripps Research Institute, La Jolla, CA, USA. Electronic address: mmacaule@scripps.edu.

Abstract

The sialic acid-binding immunoglobulin-like lectins (Siglecs) are a family of immunomodulatory receptors whose functions are regulated by their glycan ligands. Siglecs are attractive therapeutic targets because of their cell type-specific expression pattern, endocytic properties, high expression on certain lymphomas/leukemias, and ability to modulate receptor signaling. Siglec-targeting approaches with therapeutic potential encompass antibody- and glycan-based strategies. Several antibody-based therapies are in clinical trials and continue to be developed for the treatment of lymphoma/leukemia and autoimmune disease, while the therapeutic potential of glycan-based strategies for cargo delivery and immunomodulation is a promising new approach. Here we review these strategies with special emphasis on emerging approaches and disease areas that may benefit from targeting the Siglec family.

KEYWORDS:

Siglecs; antibodies; glycans; sialic acid; synthetic ligands

PMID:
26435210
PMCID:
PMC4593978
DOI:
10.1016/j.tips.2015.06.008
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center